Li Nan (LN)

SEC Form 4 insider trading activity

Li Nan (LN) has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: May 12, 2026.

On the most recent filing, Li Nan (LN) is listed as Director at Odyssey Therapeutics, Inc. Inside the rolling window, Li Nan (LN) reported 1 open-market purchase totaling $20.0M in ODTX and no open-market sales.

Companies traded

Other insiders at ODTX

Insider Buying

$20.0M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ODTX
Li Nan (LN)
Purchase$20.0MMay 12SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Li Nan (LN) made?

Li Nan (LN) has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Li Nan (LN) trade?

Li Nan (LN) has filed SEC Form 4 disclosures for 1 company, including ODTX.

When was Li Nan (LN)'s most recent SEC Form 4 filing?

Li Nan (LN)'s most recent SEC Form 4 filing on Tracefour is dated May 12, 2026.

What is Li Nan (LN)'s total buy and sell value in the current window?

Inside the rolling retention window, Li Nan (LN) bought $20.0M and sold $0 based on SEC Form 4 filings.

What was Li Nan (LN)'s largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 1,111,111 ODTX shares on 2026-05-11, worth $20.0M, per SEC Form 4 filings.